Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia

Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia

Patients with high risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) are commonly older with multiple co-morbidities, rendering them unsuitable for intensive induction chemotherapy or transplantation. We report preliminary cellular immune profiling of four cases receiving seq...

Full description

Bibliographic Details
Main Authors: Prachi Jain, Jeffrey Klotz, Neil Dunavin, Kit Lu, Eleftheria Koklanaris, Debbie Draper, Jeanine Superata, Fariba Chinian, Quan Yu, Keyvan Keyvanfar, Susan Wong, Pawel Muranski, A. John Barrett, Sawa Ito, Minoo Battiwalla
Format: Article
Language:English
Published: Elsevier 2017-01-01
Series:Leukemia Research Reports
Subjects:
Clofarabine
Lenalidomide
Immune profiling
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048917300110

Internet

http://www.sciencedirect.com/science/article/pii/S2213048917300110

Similar Items